Subscribe To
CTXR / Citius Pharmaceuticals, Inc. to Present at Upcoming March 2022 Conferences
Content Topics
Vanguard
Short
Term
Investment
Grade
Bond
Index
Fund
Institutional
Plus
Gbp
Dist
0p000147mf
Citius
Pharmaceuticals
Present
Upcoming
Conferences
Stock
CTXR
CTXR News
By Seeking Alpha
June 2, 2023
Citius Pharmaceuticals: Steer Clear From This One
The article provides an updated analysis of Citius Pharmaceuticals following a previous piece in February 2023. Citius' lead therapy has a midsummer 2 more_horizontal
By PRNewsWire
January 11, 2023
Citius Pharmaceuticals to Present at the Sidoti Micro-Cap Virtual Conference on January 18, 2023
CRANFORD, N.J. , Jan. 11, 2023 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR), a late-stage biopharmaceutical more_horizontal
By Seeking Alpha
November 8, 2022
Citius Pharmaceuticals: Large Price Action Imminent From Catalysts Within 60 Days
Citius Pharmaceuticals, Inc. has a handful of catalysts set to occur in the next few months. Of these, some are critical to extending its cash runway more_horizontal
By Seeking Alpha
July 5, 2022
Citius Pharmaceuticals: Hoping For A Turnaround Strategy
Citius Pharmaceuticals is yet to release test results a year after it was granted positive recommendation by the Independent Data Monitoring Committee more_horizontal
By PRNewsWire
April 14, 2022
Citius Pharmaceuticals to Present at the NobleCon18 Investor Conference on April 20, 2022
CRANFORD, N.J. , April 14, 2022 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR), a late-stage biopharmaceutica more_horizontal
By Zacks Investment Research
April 7, 2022
Citius (CTXR) Posts Top-Line Data From Pivotal Lymphoma Study
Citius (CTXR) releases encouraging top-line data from the phase III study on I/ONTAK for the treatment of persistent or recurrent cutaneous T-cell lym more_horizontal
By Market Watch
April 6, 2022
Shares of Citius jump 18% on new data for experimental lymphoma drug
Shares of Citius Pharmaceuticals Inc. CTXR, -1.60% were up 18.5% in premarket trading on Wednesday after the company shared positive topline data from more_horizontal
By Seeking Alpha
March 28, 2022